Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $970 | In Stock | |
25 mg | $1,520 | In Stock | |
50 mg | $1,980 | In Stock | |
1 mL x 10 mM (in DMSO) | $37 | In Stock |
Description | Pitavastatin (NK-104) is a potent inhibitor of hydroxymethylglutaryl-CoA (HMG-CoA) reductase, effectively inhibiting cholesterol synthesis from acetic acid in HepG2 cells with an IC50 of 5.8 nM. It also induces hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptors and exhibits therapeutic activities such as anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective, and reno-protective effects. |
In vitro | Pitavastatin inhibits the growth of a panel of ovarian cancer cells, including those likely representing HGSOC, with IC50 values of 0.4-5 μM in monolayers and 0.6-4 μM in spheroids [4]. At 1 μM for 48 hours, Pitavastatin induces apoptosis in Ovcar-8 and Ovcar-3 cells, increasing the activity of caspases-3, -7, -8, and -9, and results in PARP cleavage in Ovcar-8 cells, as evidenced by Western Blot analysis [1, 4]. |
In vivo | In 4-week-old female NCR Nu/Nu nude mice bearing Ovcar-4 tumors, Pitavastatin (administered at a dose of 59 mg/kg; orally (p.o.); twice daily for 28 days) is able to significantly induce tumor regression[4]. |
Alias | NK104, NK 104, NK-104 |
Molecular Weight | 421.46 |
Formula | C25H24FNO4 |
Cas No. | 147511-69-1 |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | ||||||||||||||||||||||||||||||
Solubility Information | DMSO: 80 mg/mL (94.91 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.